HNWAG
SNDX icon

High Net Worth Advisory Group’s Syndax Pharmaceuticals SNDX Stock Holding History

High Net Worth Advisory Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,500
Closed -$63.6K – 515
2022
Q4 		$63.6K Sell
2,500
-500
-17% -$11.7K 0.02% 288
2022
Q3 		$72K Buy
3,000
+1,000
+50% +$22.4K 0.03% 274
2022
Q2 		$38K Hold
2,000
– – 0.02% 363
2022
Q1 		$35K Hold
2,000
– – 0.01% 385
2021
Q4 		$44K Buy
+2,000
New +$37K 0.02% 364

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

High Net Worth Advisory Group's SNDX Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 2,500 shares — an estimated $63.6K sold.

High Net Worth Advisory Group first reported a position in SNDX in Q4 2021 and held it in 5 quarters. The position peaked at $72K in Q3 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 2,500 Syndax Pharmaceuticals shares in Q1 2023, an estimated $63.6K.
  • High Net Worth Advisory Group first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • High Net Worth Advisory Group's Syndax Pharmaceuticals position peaked at $72K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.